Boston Scientific Corporation vs iShares MSCI Malaysia ETF — how do they compare? Boston Scientific Corporation trades at $42.65 (market cap $66.37B), while iShares MSCI Malaysia ETF trades at $28.03. The key difference: iShares MSCI Malaysia ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | EWM | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $108.14 | $30.42 |
52-Week Low | $42.63 | $23.49 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
EWM (iShares MSCI Malaysia ETF) trades at $27.50, up 0.26% with a bullish technical signal despite mixed moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. RSI levels show potential overbought conditions near-term, while ADX indicates strong trend momentum. Support and resistance cluster around $27-$28 levels.
Outlook remains cautiously optimistic given Malaysia's economic initiatives, though concentrated sector exposure and regional geopolitical risks warrant monitoring. The dividend scheduled for June 2026 provides income appeal, while technical indicators suggest potential consolidation near current levels before further directional moves.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →